[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc (PRLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Prelude Therapeutics Inc 175 Innovation Boulevard Wilmington DE 19805 USA

www.preludetx.com Employees: 79 P: 302-467-1280

Sector:

Medical

Description:

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. It is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorporated is based in Wilmington, United States.

Key Statistics

Overview:

Market Capitalization, $K 391,057
Enterprise Value, $K 355,797
Shares Outstanding, K 79,645
Float, K 40,460
% Float 50.80%
Short Interest, K 1,793
Short Float 2.25%
Days to Cover 6.28
Short Volume Ratio 0.40
% of Insider Shareholders 49.20%
% of Institutional Shareholders 79.72%

Financials:

Annual Sales, $ 12,140 K
Annual Net Income, $ -99,500 K
Last Quarter Sales, $ 4,580 K
Last Quarter Net Income, $ -10,390 K
EBIT, $ -84,140 K
EBITDA, $ -82,800 K

Growth:

1-Year Return 513.75%
3-Year Return 11.34%
5-Year Return -82.77%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 71.71%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.13 on 05/12/26
Next Earnings Date 08/13/26
Earnings Per Share ttm -1.00
EPS Growth vs. Prev Qtr 35.00%
EPS Growth vs. Prev Year 69.05%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

PRLD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -118.24%
Return-on-Assets % -66.12%
Profit Margin % -819.60%
Debt/Equity 0.00
Price/Sales 32.21
Price/Cash Flow N/A
Price/Book 5.14
Book Value/Share 0.95
Interest Coverage -3.44
60-Month Beta 0.95
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.